Research programme: selective estrogen receptor modulator derivatives - Pharmos Corporation
Latest Information Update: 03 Dec 2007
At a glance
- Originator Pharmos Corporation
- Class
- Mechanism of Action Angiogenesis inhibitors; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Osteoporosis
Most Recent Events
- 13 Jun 2006 No development reported - Preclinical for Cancer (Prevention)/Chemoprevention in USA (unspecified route)
- 13 Jun 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 13 Jun 2006 No development reported - Preclinical for Osteoporosis in USA (unspecified route)